Control of Proclactin Secretion

Flückiger, E.; Pozo, E. del; Werder, Klaus von

doi:10.1007/978-3-642-81721-2_2

Cited by 5 publications

(3 citation statements)

References 460 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Activated Tregs produce more dopamine than Teffs in general. In addition, DA can indirectly affect tumor growth by regulating the production and release of prolactin (76)(77)(78), which regulates the function of NK cells and lymphokineactivated killer cells (79).…”

Section: Dopaminementioning

confidence: 99%

Neurotransmitters: promising immune modulators in the tumor microenvironment

Xiao

Fang

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

The tumor microenvironment (TME) is modified by its cellular or acellular components throughout the whole period of tumor development. The dynamic modulation can reprogram tumor initiation, growth, invasion, metastasis, and response to therapies. Hence, the focus of cancer research and intervention has gradually shifted to TME components and their interactions. Accumulated evidence indicates neural and immune factors play a distinct role in modulating TME synergistically. Among the complicated interactions, neurotransmitters, the traditional neural regulators, mediate some crucial regulatory functions. Nevertheless, knowledge of the exact mechanisms is still scarce. Meanwhile, therapies targeting the TME remain unsatisfactory. It holds a great prospect to reveal the molecular mechanism by which the interplay between the nervous and immune systems regulate cancer progression for laying a vivid landscape of tumor development and improving clinical treatment.

show abstract

Section: Dopaminementioning

confidence: 99%

Neurotransmitters: promising immune modulators in the tumor microenvironment

Xiao

Fang

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Together with the studies that allowed the mapping and identification of catecholaminergic and serotoninergic pathways in the central nervous system by using the Falck-Hillarp fluorescent method first, and immunohistochemical methods later [10,11], and the identification of selective receptors for each monoamine across the brain [12][13][14][15][16][17][18][19][20], the most important brain dopaminergic systems (e.g., nigrostriatal, mesolimbic-mesocortical, incertohypothalamic and tuberoinfundibular systems) were described and found thereafter to be deeply involved in different central functions (see [21]). Among these are motor and posture control (lesions of nigrostriatal dopaminergic neurons produce Parkinson disease symptoms) [22][23][24], motivation and reward processes (alterations of the activity of mesolimbic/mesocortical dopaminergic neurons interfere with motivation and rewarding processes and are involved in drug dependence and addiction) (see [25,26]), thought, ideation and reasoning (alterations in the activity of mesolimbic/mesocortical dopaminergic system take place in psychosis and schizophrenia) [9,12,16,27,28] and hypothalamic control of prolactin release from the adenohypophysis (tuberoinfundibular neurons release dopamine from the median eminence in the hypophysial blood portal system, allowing it to reach the adenohypophysis, where the catecholamine acts to inhibit prolactin release) [29][30][31] (Table 1). Details are in References [9,12,[22][23][24][25][26][27][28]…”

Section: Introductionmentioning

confidence: 99%

“…Among these are motor and posture control (lesions of nigrostriatal dopaminergic neurons produce Parkinson disease symptoms) [22][23][24], motivation and reward processes (alterations of the activity of mesolimbic/mesocortical dopaminergic neurons interfere with motivation and rewarding processes and are involved in drug dependence and addiction) (see [25,26]), thought, ideation and reasoning (alterations in the activity of mesolimbic/mesocortical dopaminergic system take place in psychosis and schizophrenia) [9,12,16,27,28] and hypothalamic control of prolactin release from the adenohypophysis (tuberoinfundibular neurons release dopamine from the median eminence in the hypophysial blood portal system, allowing it to reach the adenohypophysis, where the catecholamine acts to inhibit prolactin release) [29][30][31] (Table 1). Details are in References [9,12,[22][23][24][25][26][27][28][29][30][31].…”

Section: Introductionmentioning

confidence: 99%

Dopamine, Erectile Function and Male Sexual Behavior from the Past to the Present: A Review

2022

View full text Add to dashboard Cite

Early and recent studies show that dopamine through its neuronal systems and receptor subtypes plays different roles in the control of male sexual behavior. These studies show that (i) the mesolimbic/mesocortical dopaminergic system plays a key role in the preparatory phase of sexual behavior, e.g., in sexual arousal, motivation and reward, whereas the nigrostriatal system controls the sensory-motor coordination necessary for copulation, (ii) the incertohypothalamic system is involved in the consummatory aspects of sexual behavior (penile erection and copulation), but evidence for its role in sexual motivation is also available, (iii) the pro-sexual effects of dopamine occur in concert with neural systems interconnecting the hypothalamus and preoptic area with the spinal cord, ventral tegmental area and other limbic brain areas and (iv) D2 and D4 receptors play a major role in the pro-sexual effects of dopamine. Despite some controversy, increases or decreases, respectively, of brain dopamine activity induced by drugs or that occur physiologically, usually improves or worsens, respectively, sexual activity. These findings suggest that an altered central dopaminergic tone plays a role in mental pathologies characterized by aberrant sexual behavior, and that pro-erectile D4 receptor agonists may be considered a new strategy for the treatment of erectile dysfunction in men.

show abstract

Effects of bromocriptine on prolactin-secreting pituitary adenomas. Mechanism of reduction in tumor size evaluated by light and electron microscopic, immunohistochemical, and morphometric analysis

Mori

Saitoh

et al. 1985

Cancer

View full text Add to dashboard Cite

Prolactin-secreting pituitary adenomas were studied to clarify the mechanism by which bromocriptine reduces tumor size. Patients examined consisted of three groups: Group I (four cases) received no medication, Group II (six cases) continued bromocriptine treatment (10 mg/day for 2 weeks) until the operation, and Group III (five cases) discontinued the treatment 1 week before the operation. Adenomas in Group II showed a variety of degenerative and necrotic changes of tumor cells in addition to marked decrease in volume of individual cell. Adenomas in Group III showed divergent structural changes. Irreversible changes seen in Group II became more pronounced with a marked increase in stromal tissue. Proliferative areas consisting of intermediate-sized cells were found in the scarce stromal tissue. The findings seem to indicate that the reduction in size of prolactinomas by bromocriptine treatment results from the reduction in size of individual tumor cell as well as from cell loss secondary to necrosis.

show abstract

Control of Proclactin Secretion

Cited by 5 publications

References 460 publications

Neurotransmitters: promising immune modulators in the tumor microenvironment

Neurotransmitters: promising immune modulators in the tumor microenvironment

Dopamine, Erectile Function and Male Sexual Behavior from the Past to the Present: A Review

Effects of bromocriptine on prolactin-secreting pituitary adenomas. Mechanism of reduction in tumor size evaluated by light and electron microscopic, immunohistochemical, and morphometric analysis

Contact Info

Product

Resources

About